3D Printing Media Network reported “Prellis Biologics to provide human lymph node organoids for research” and announced the startup will leverage its external human immune system (EXIS) in a collaboration and licensing agreement with the healthcare giant Sanofi. Prellis Biologics (SOSV IBSF05 2017) engineers fully-human lymph node organoids (LNOs) and recreates immune responses in vitro to deliver antibodies with significant genetic diversity.

The piece quotes Melanie Matheu, PhD, Founder and CEO of Prellis Biologics: “This powerful technology enables investigation of human B- and T-cell responses for a variety of applications, including antibody discovery and therapeutic immunogenicity. We are delighted to work in collaboration with Sanofi in novel antibody research with our differentiated approach.”